BAOTOU DONGBAO BIO-TECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.24 CNY | +3.15% |
|
+10.32% | -15.89% |
| 04-24 | Baotou Dongbao Bio-Tech Co.,Ltd Proposes Final Cash for the Year 2023 | CI |
| 04-23 | Baotou Dongbao Bio-Tech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 943M 130M 179M | Sales 2023 | 975M 135M 185M | Capitalization | 3.7B 511M 703M |
|---|---|---|---|---|---|
| Net income 2022 | 109M 15.06M 20.73M | Net income 2023 | 120M 16.58M 22.82M | EV / Sales 2022 | 4.55 x |
| Net cash position 2022 | 161M 22.24M 30.62M | Net cash position 2023 | 279M 38.59M 53.14M | EV / Sales 2023 | 3.51 x |
| P/E ratio 2022 |
40.7
x | P/E ratio 2023 |
31.8
x | Employees | 1,356 |
| Yield 2022 |
0.35% | Yield 2023 |
-
| Free-Float | 31.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.15% | ||
| 1 week | +10.32% | ||
| Current month | +1.95% | ||
| 1 month | +1.95% | ||
| 3 months | -1.69% | ||
| 6 months | -15.89% | ||
| Current year | -15.89% |
1 week
4.73
5.30
1 month
4.595.34
Current year
3.636.40
1 year
3.636.80
3 years
3.639.39
5 years
3.639.85
10 years
3.3914.68
| Managers | Title | Age | Since |
|---|---|---|---|
Fang Liu
CEO | Chief Executive Officer | 60 | 21-09-09 |
Haiqing Hao
DFI | Director of Finance/CFO | 48 | 19-04-16 |
Yan Liu
BRD | Director/Board Member | 37 | 21-09-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ai Guo Wang
CHM | Chairman | 55 | 21-09-09 |
De Bu Gao
BRD | Director/Board Member | 69 | 20-05-11 |
Fang Liu
CEO | Chief Executive Officer | 60 | 21-09-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 5.24 | +3.15% | 17,897,880 |
| 24-04-29 | 5.08 | +3.67% | 11,549,770 |
| 24-04-26 | 4.9 | +0.82% | 6,509,827 |
| 24-04-25 | 4.86 | +0.62% | 5,175,600 |
| 24-04-24 | 4.83 | -1.02% | 7,038,876 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Baotou Dongbao Bio-Tech Co., Ltd is principally engaged in the research, development, manufacture and distribution of gelatin series products and low molecular mass collagen. The Company primarily provides gelatin, which is used in the manufacture of empty capsules and food additives; calcium hydrophosphate, which is used in feed additives, as well as collagen series products, which are used in foods, cosmetics, health care products. The Company distributes its products in both domestic and overseas markets, with domestic markets as its major markets.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -15.89% | 430M | |
| +19.27% | 43.18B | |
| +24.05% | 23.23B | |
| +15.11% | 14.6B | |
| +38.36% | 11.5B | |
| -7.63% | 6.79B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.31B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- 300239 Stock
